Home ›
Lymphoma Trials ›
NCT07231952
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
The purpose of this study is to find out if the combination of pirtobrutinib, venetoclax, and rituximab is an effective treatment for participants with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)
Trial Details
NCT ID NCT07231952
Phase PHASE2
Sponsor Memorial Sloan Kettering Cancer Center
Status RECRUITING
Cancer Type Lymphoma
Interventions Pirtobrutinib Venetoclax Rituximab
Locations (sample) Boston, Massachusetts, United States|42.35843,-71.05977 Boston, Massachusetts, United States|42.35843,-71.05977 Basking Ridge, New Jersey, United States|40.70621,-74.54932 Middletown, New Jersey, United States|40.39428,-74.11709 Montvale, New Jersey, United States|41.04676,-74.02292
Key Eligibility Criteria
Age greater than or equal to 18 years Histologically confirmed treatment naive WM/LPL (participants with non-IgM LPL are NOT eligible for the study) Patients must have measurable disease as defined by at least one lymph node ≥1.5 cm and/ or IgM levels \> 0.5gm/dl quantified by using densitometry… Participants must have at least one of the established criteria to require therapy for WM, including anemia, thrombocytopenia, neuropathy related t…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →